Farrar, Danielle C.
,
Mian, Asim Z.
Budson, Andrew E.
Moss, Mark B.
Koo, Bang Bon
Killiany, Ronald J.
Funding for this research was provided by:
National Institutes of Health (AG024904)
U.S. Department of Defense (W81XWH-12-2-0012)
Article History
Received: 28 March 2017
Revised: 7 June 2017
Accepted: 15 June 2017
First Online: 10 July 2017
Compliance with ethical standards
:
: The scientific guarantor of this publication is Ron Killiany, PhD.
: The conflicts of interest are as follows: Dr. Budson has been an investigator for clinical trials for the following companies: AstraZenica, Hoffmann-La Roche, Eli Lily, FORUM Pharmaceuticals, and Neuronetrix. Dr. Moss serves as a consultant for Pfizer, Inc. Dr. Killiany is funded on two research grants from Pfizer, Inc. Dr. Mian is a shareholder of Boston Imaging Core Lab.
: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (ExternalRef removed). The grantee organisation is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
: Danielle Farrar, MA performed the statistical analysis for this paper, with input from Dr. Ronald J. Killiany.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: This study was performed using data from the Alzheimer’s Disease Neuroimaging Initiative. Other studies published utilizing this dataset can be found at ExternalRef removed
: • retrospective• cross-sectional study• multicentre study